Coherus Oncology (FRA:8C5) Short Percentage of Float


FRA:8C5 Coherus Oncology Inc FRA:8C5
45 GF Score
Price €1.26
GF Value €0.69
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Coherus Oncology Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:8C5 vs TARA, KPTI, CNTN: Short Percentage of Float Comparison

For the Biotechnology subindustry, Coherus Oncology's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus Oncology Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's Short Percentage of Float falls into.


FRA:8C5
45GF Score
Coherus Oncology Inc FRA:8C5
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.26 is trading 82.2% above its estimated GF Value™ of €0.69. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for FRA:8C5:

  • Short Percentage of Float:
  • GF Value™: €0.69 vs. price of €1.26 (82.2% above fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges CHRS:USA
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
45GF Score

Get the complete analysis for FRA:8C5

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.26
Price
€0.69
GF Value